{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T21:58:50Z","timestamp":1789595930806,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.msard.2021.102988","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T03:08:21Z","timestamp":1619838501000},"page":"102988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases"],"prefix":"10.1016","volume":"52","author":[{"given":"N.R.","family":"Oksbjerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-7455","authenticated-orcid":false,"given":"S.D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Blinkenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1333-9623","authenticated-orcid":false,"given":"F.","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2021.102988_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"11","key":"10.1016\/j.msard.2021.102988_bib0002","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1002\/art.34584","article-title":"Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center","volume":"64","author":"Cartin-Ceba","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.msard.2021.102988_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102420","article-title":"Infections in patients with multiple sclerosis: a national cohort study in Sweden","volume":"45","author":"Castelo-Branco","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2021.102988_bib0004","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9856","key":"10.1016\/j.msard.2021.102988_bib0005","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2021.102988_bib0006","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"S2","key":"10.1016\/j.msard.2021.102988_bib0007","first-page":"20","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"25","author":"Derfuss","year":"2019","journal-title":"Mult. Scler."},{"issue":"5","key":"10.1016\/j.msard.2021.102988_bib0008","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.102988_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40259-018-0327-9","article-title":"Monoclonal antibodies for multiple sclerosis: an update","volume":"33","author":"Graf","year":"2019","journal-title":"BioDrugs"},{"issue":"3","key":"10.1016\/j.msard.2021.102988_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.msard.2021.102988_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102466","article-title":"Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia","volume":"19","author":"Kridin","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.msard.2021.102988_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2581","article-title":"Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis","author":"Louapre","year":"2020","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.102988_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102988_bib0014","doi-asserted-by":"crossref","first-page":"e01921","DOI":"10.1002\/brb3.1921","article-title":"The Danish multiple sclerosis registry","volume":"11","author":"Magyari","year":"2021","journal-title":"Brain Behav."},{"issue":"6","key":"10.1016\/j.msard.2021.102988_bib0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol. \u2013 Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102988_bib0016","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskel. Disord."},{"issue":"3","key":"10.1016\/j.msard.2021.102988_bib0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2021.102988_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9124067","article-title":"Experience in multiple sclerosis patients with COVID-19 and disease-modifying therapies: a review of 873 published cases","volume":"9","author":"M\u00f6hn","year":"2020","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.msard.2021.102988_bib0019","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2021.102988_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.101982","article-title":"Infections in patients diagnosed with multiple sclerosis: a multi-database study","volume":"41","author":"Persson","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2021.102988_bib0021","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1177\/1352458515594042","article-title":"Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients","volume":"22","author":"Radaelli","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102988_bib0022","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2021.102988_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.0688","article-title":"Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis","author":"Salter","year":"2021","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.102988_bib0024","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.msard.2021.102988_bib0025","doi-asserted-by":"crossref","unstructured":"Simpson-Yap, S., De Brouwer, E., Kalincik, T., Rijke, N., Hillert, J., Walton, C., Edan, G., Moreau, Y., Spelman, T., Geys, L., Parciak, T., Gautrais, C., Lazovski, N., Pirmani, A., Ardeshirdavani, A., Forsberg, L., Glaser, A., McBurney, R., Schmidt, H., Bergmann, A., Braune, S., Stahmann, A., Middleton, R., Salter, A., Fox, R.J., van der Walt, A., Butzkueven, H., Al-Roughani, R., Ozakbas, S., Rojas, J.I., van der Mei, I., Nag, N., Ivanov, R., do Olival, G.S., Dias, A.E., Magyari, M., Guimar\u00e3es Brum, D., Mendes, M.F., Alonso, R., Nicholas, R., Bauer, J., Chertcoff, A., Zabalza, A., Arrambide, G., Fidao, A., Comi, G., Peeters, L.M., 2021. Associations of DMT therapies with COVID-19 severity in multiple sclerosis. medRxiv, 2021.2002.2008.21251316.","DOI":"10.1101\/2021.02.08.21251316"},{"issue":"3","key":"10.1016\/j.msard.2021.102988_bib0026","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/ane.12712","article-title":"Safety concerns and risk management of multiple sclerosis therapies","volume":"136","author":"Soelberg Sorensen","year":"2017","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2021.102988_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26028","article-title":"Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis","author":"Sormani","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102988_bib0028","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12913-019-4412-7","article-title":"Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults \u226550\u2009years-old","volume":"19","author":"Trucchi","year":"2019","journal-title":"BMC Health Serv. Res."},{"issue":"9","key":"10.1016\/j.msard.2021.102988_bib0029","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.msard.2021.102988_bib0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2014.19.1.20667","article-title":"The Danish Microbiology Database (MiBa) 2010 to 2013","volume":"19","author":"Voldstedlund","year":"2014","journal-title":"Euro Surveill."},{"issue":"10","key":"10.1016\/j.msard.2021.102988_bib0031","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp-2017-317493","article-title":"Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study","volume":"89","author":"Wijnands","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2021.102988_bib0032","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2016.21","article-title":"Disease-modifying therapies and infectious risks in multiple sclerosis","volume":"12","author":"Winkelmann","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2021.102988_bib0033","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.102988_bib0034","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2020.2065","article-title":"Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review","author":"Zubair","year":"2020","journal-title":"JAMA Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821002558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:41Z","timestamp":1761900761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821002558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":34,"alternative-id":["S2211034821002558"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102988","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102988"}}